Utility valuations for outcome states of colorectal cancer

American Journal of Gastroenterology

Volumn 94, Issue 6, 1999, Pages 1650-1657

  Ness, Reid M ^a   Holmes, Ann M ^a   Klein, Robert ^a   Dittus, Robert ^b  

^a INDIANA UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADENOMA; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DECISION SUPPORT TECHNIQUES; ENTEROSTOMY; FEMALE; FORECASTING; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NEOPLASM STAGING; RECTAL NEOPLASMS;

EID: 0032976480     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1999.01157.x     Document Type: Article

References (41)

1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1998. CA Cancer J Clin. 48:1998;6-29.
2. Winawer S.J., Zauber A.G., Ho M.N., et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 329:1993;1977-1981.
3. Mandel J.S., Bond J.H., Church T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 328:1993;1365-1371.
4. Hardcastle J.D., Chamberlain J.O., Robinson M.H., et al. Randomised controlled trial of faecal- occult-blood screening for colorectal cancer. Lancet. 348:1996;1472-1477.
5. Kronborg O., Fenger C., Olsen J., et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 348:1996;1467-1471.
6. Weinstein M.C., Siegel J.E., Gold M.R., et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 276:1996;1253-1258.
7. Russell L.B., Gold M.R., Siegel J.E., et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 276:1996;1172-1177.
8. Kaplan R.M., Feeny D., Revicki D.A. Methods for assessing relative importance in preference based outcome measures. Qual Life Res. 2:1993;467-475.
9. Dominitz J.A., Provenzale D. Patient preferences and quality of life associated with colorectal cancer screening. Am J Gastroenterol. 92:1997;2171-2178.
10. Whynes D.K., Neilson A.R. Convergent validity of two measures of the quality of life. Health Econ. 2:1993;229-235.
11. Sprangers M.A., Taal B.G., Aaronson N.K., et al. Quality of life in colorectal cancer. Stoma vs. nonstoma patients. Dis Colon Rectum. 38:1995;361-369.
12. Cohen A.M., Minsky B.D., Schilsky R.L. Cancer of the colon. DeVita V.T. Jr, Hellman S., Rosenburg S.A. Cancer Principles and practice of oncology . 4th ed. 1997;1144-1197 Lippincott-Raven, Philadelphia.
13. Cohen A.M., Minsky B.D., Schilsky R.L. Cancer of the rectum. DeVita V.T. Jr, Hellman S., Rosenburg S.A. Cancer Principles and practice of oncology . 4th ed. 1997;1197-1234 Lippincott-Raven, Philadelphia.
14. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 322:1990;352-358.
15. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 345:1995;939-944.
16. van Driel M.F., Weymar Schultz W.C., van de Wiel H.B., et al. Female sexual functioning after radical surgical treatment of rectal and bladder cancer. Eur J Surg Oncol. 19:1993;183-187.
17. Krook J.E., Moertel C.G., Gunderson L.L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 324:1991;709-715.
18. O'Connell M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 331:1994;502-507.
19. Glimelius B., Hoffman K., Graf W., et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer. 73:1994;556-562.
20. Ness R.M., Holmes A., Klein R., et al. Outcome states of colorectal cancer Identification and description using patient focus groups . Am J Gastroenterol. 93:1998;1491-1497.
21. Patrick D.L., Starks H.E., Cain K.C., et al. Measuring preferences for health states worse than death. Med Decis Mak. 14:1994;9-18.
22. Froberg D.G., Kane R.L. Methodology for measuring health state preferences I Measurement strategies . J Clin Epidemiol. 42:1989;345-354.
23. Patrick D.L., Erickson P. Health status and health policy. 1993;Oxford University Press, New York.
24. Froberg D.G., Kane R.L. Methodology for measuring health-state preferences II Scaling methods . J Clin Epidemiol. 42:1989;459-471.
25. Gold M.R., Patrick D.L., Torrance G.W., et al. Identifying and valuing outcomes. Gold M.R., Siegel J.E., Russell L.B., et al. Cost-effectiveness in health and medicine. 1996;82-134 Oxford University Press, New York.
26. Froberg D.G., Kane R.L. Methodology for measuring health state preferences III Population and context effects . J Clin Epidemiol. 42:1989;585-592. (abstract).
27. O'Connor A.M., Boyd N.F., Tritchler D.L., et al. Eliciting preferences for alternative cancer drug treatments. The influence of framing, medium, and rater variables. Med Decis Mak. 5:1985;453-463.
28. Carter W.B., Bobbitt R.A., Bergner M., et al. Validation of an interval scaling The sickness impact profile . Health Serv Res. 11:1976;516-528.
29. Rosser R., Kind P. A scale of valuations of states of illness Is there a social consensus? Int J Epidemiol. 7:1978;347-358.
30. Sackett D.L., Torrance G.W. The utility of different health states as perceived by the general public. J Chronic Dis. 31:1978;697-704.
31. Llewellyn-Thomas H., Sutherland H.J., Tibshirani R., et al. Describing health states. Methodologic issues in obtaining values for health states. Med Care. 22:1984;543-552.
32. Balaban D.J., Sagi P.C., Goldfarb N.I., et al. Weights for scoring the quality of well-being instrument among rheumatoid arthritics. A comparison to general population weights. Med Care. 24:1986;973-980.
33. Boyle M.H., Torrance G.W. Developing multiattribute health indexes. Med Care. 22:1984;1045-1057.
34. Patrick D.L., Sittampalam Y., Somerville S.M., et al. A cross-cultural comparison of health status values. Am J Public Health. 75:1985;1402-1407.
35. Hadorn D.C., Sorensen J., Holte J. Large-scale health outcomes evaluation How should quality of life be measured? Part II - Questionnaire validation in a cohort of patients with advanced cancer . J Clin Epidemiol. 48:1995;619-629.
36. Llewellyn-Thomas H.A., Sutherland H.J., Thiel E.C. Do patients' evaluations of a future health state change when they actually enter that state? Med Care. 31:1993;1002-1012.
37. Najman J.M., Levine S. Evaluating the impact of medical care and technologies on the quality of life A review and critique . Soc Sci Med. 15:1981;107-115.
38. Epstein A.M., Hall J.A., Tognetti J., et al. Using proxies to evaluate quality of life. Can they provide valid information about patients' health status and satisfaction with medical care? Med Care. 27:1989;S91-S98.
39. Slevin M.L., Stubbs L., Plant H.J., et al. Attitudes to chemotherapy Comparing views of patients with cancer with those of doctors, nurses, and general public . Br Med J. 300:1990;1458-1460.
40. Boyd N.F., Sutherland H.J., Heasman K.Z., et al. Whose utilities for decision analysis? Med Decis Mak. 10:1998;58-67.
41. Brazier J., Dixson S. The use of condition specific outcome measures in economic appraisal. Health Econ. 4:1995;255-264.